50 completed, 7 recruiting, 4 not yet recruiting, 1 terminated. 45 Phase 1, 11 Not applicable, 4 Early Phase 1, 2 Phase 2.
Follow Healthy Volunteer Study: new trials by email Literature Review of Healthy Volunteer Study trials Research Report on Healthy Volunteer Study
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety Study of CZ10 in Healthy Volunteers Contrast Media, Placebo - Healthy Volunteer Study | Phase 1 | Not yet recruiting | Nextrast, Inc. | 24 | 2050-01-01 | 2024-11-29 |
| A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma PF-08103402, Placebo, Midazolam - Healthy Volunteer Study, Healthy Adults | Phase 1 | Recruiting | Pfizer | 133 | 2026-06-17 | 2026-10-13 |
| Pain Induced by m-Cresol as Preservative m-Cresol 0.1%, m-Cresol 0.25%, Control Solution - Pain, Acute Pain | Early Phase 1 | Not yet recruiting | Medical University of Vienna | 18 | 2026-05-25 | 2026-05-22 |
| The Role of NaV1.8 in Human Pain Models Suzetrigine, Lidocaine (drug), Control Solution - Pain, Acute Pain | Early Phase 1 | Completed | Medical University of Vienna | 67 | 2026-04-21 | 2026-06-24 |
| The Kidney's Response to Exercise in Heat, and the Impact of Vitamin B3 on This Response Vitamin B3 - Heat Strain, Healthy Volunteer Study | Early Phase 1 | Recruiting | Beth Israel Deaconess Medical Center | 28 | 2026-01-26 | 2026-02-05 |
| Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG) Ethinyl Estradioll/Levonorgestrel (EE/LNG), Bemnifosbuvir/Ruzasvir (BEM/RZR), Bemnifosbuvir/Ruzasvir (BEM/RZR) + Ethinyl Estradioll/Levonorgestrel (EE/LNG) - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 24 | 2025-12-04 | 2026-04-13 |
| A Multi-domain Intervention for Healthy Aging Multidomain Intervention, General activities - Healthy Volunteer Study | Not applicable | Recruiting | University of Bari | 100 | 2025-10-01 | 2025-01-09 |
| Near-InfraRed Spectroscopy of Auricular Stimulation auricular stimulation - Healthy Male and Female Subjects, Healthy Volunteer Study | Not applicable | Recruiting | University of Pittsburgh | 80 | 2025-08-12 | 2026-02-18 |
| Muscle Vibration as a Countermeasure Against Hypoactivity-induced Focal muscle vibration, NO Focal muscle vibration - Vibration Therapy, Healthy Volunteer Study | Not applicable | Recruiting | Centre Hospitalier Universitaire de Saint Etienne | 42 | 2025-06-16 | 2026-05-26 |
| An Investigation to Evaluate Wearing Properties of Three Different Investigational Devices Dressing - Healthy Volunteer Study | Not applicable | Recruiting | Molnlycke Health Care AB | 35 | 2025-06-05 | 2025-06-24 |
| Differential Learning Enhances Motor Performance and Retention in Sport Science Students Differential Learning, Blocked Practice - Healthy Volunteer Study | Not applicable | Completed | The Higher Institute of Sport and Physical Education of Sfax | 100 | 2025-06-02 | 2026-06-05 |
| Stomach Processing and Emptying Evaluation With Diet and Ultrasound Physical activity after different type of meals - Gastric Emptying, Preoperative Risk Assessment | Not applicable | Not yet recruiting | Medical University of Warsaw | 60 | 2025-06-01 | 2025-05-23 |
| Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting, Treatment B-Omeprazole 20 mg dose administered fasting, Treatment C-Bemnifosbuvir/Ruzasvir FDC administered simultaneously with 20 mg dose of Omeprazole fasting - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 20 | 2025-05-09 | 2025-08-29 |
| Exploratory Clinical Study to Assess Safety and Efficacy of Xenon Gas Inhalation to Control Neuroinflammation Xenon gas inhalation - Healthy Volunteer Study | Phase 1 | Recruiting | General Biophysics LLC | 16 | 2025-04-16 | 2025-04-25 |
| Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination - Healthy Volunteer Study, Hepatic Impairment | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 28 | 2025-04-09 | 2026-07-31 |
| Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin Digoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR, Rosuvastatin vs Rosuvastatin + BEM/RZR vs Rosuvastatin + 2h BEM/RZR - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 38 | 2025-04-08 | 2025-08-29 |
| A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations ALG-055009 - Healthy Volunteer Study | Phase 1 | Completed | Aligos Therapeutics | 8 | 2025-03-25 | 2025-07-09 |
| Measurement of the Optic Nerve Diameter in Different Healthcare Operators Training - Healthy Volunteer, Healthy Volunteer Study | Not applicable | Not yet recruiting | University Magna Graecia | 40 | 2025-03-01 | 2025-02-17 |
| A Phase 1 Study of CG001419 Administered Orally in Healthy Subjects CG001419, Placebo - Healthy Volunteer Study, Pain Management | Phase 1 | Completed | Cullgen Australia Pty Ltd | 72 | 2025-01-22 | 2026-02-20 |
| Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function semaglutide, Placebo - Healthy Volunteer Study, HPA | Not applicable | Completed | University Hospital, Basel, Switzerland | 22 | 2025-01-16 | 2026-02-11 |
Showing 20 of 62. Sign in to see all of them.
Acute Pain (3) · Pain (2) · Acute Radiation Syndrome (1) · Adrenal Insufficiency (1) · Agnosia (1) · Asthma (1) · Chronic Pain (1) · Common Cold (1) · Edema (1) · Erythema (1) · Medication Adherence (1) · Opioid-Related Disorders (1) · Renal Insufficiency (1) · Respiratory Aspiration (1) · Sedentary Behavior (1)
Pathological Conditions, Signs and Symptoms (6) · Signs and Symptoms (5) · Neurologic Manifestations (4) · Respiratory Tract Diseases (3) · Behavior (2) · Adrenal Gland Diseases (1) · Bronchial Diseases (1) · Chemically-Induced Disorders (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Health Behavior (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1) · Immune System Diseases (1)
AT-511 (12) · Oxytocin (3) · ruzasvir (3) · Ibuprofen (2) · Midazolam (2) · Tablets (2) · Acetaminophen (1) · Azithromycin (1) · Bandages (1) · Buprenorphine (1) · Carbamazepine (1) · Contrast Media (1) · Cyclosporine (1) · Fluticasone-Salmeterol Drug Combination (1) · LY 2140023 (1)
Atea Pharmaceuticals, Inc. (18) · Orion Corporation, Orion Pharma (3) · Wake Forest University Health Sciences (3) · Medical University of Vienna (2) · Pfizer (2) · Reckitt Benckiser Healthcare (UK) Limited (2) · Aligos Therapeutics (1) · AstraZeneca (1) · BenevolentAI Bio (1) · Beth Israel Deaconess Medical Center (1) · BioAge Labs, Inc. (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Comanche Biopharma (1) · Cullgen Australia Pty Ltd (1) · Dauntless Pharmaceuticals (1)
United States (21) · Canada (12) · United Kingdom (9) · Australia (3) · Finland (2) · France (2) · Germany (2) · Italy (2) · Austria (1) · China (1) · Netherlands (1) · New Zealand (1) · Poland (1) · Switzerland (1) · Tunisia (1)
James C Eisenach, MD (3) · Allison August, MD (1) · Denisa Wilkes (1) · Dr. Uta Solecke (1) · Federico Longhini, MD (1) · Girish Sharma, MBBS (1) · Haleema Shakur-Still (1) · Howard L Weiner, MD (1) · Ian Roberts (1) · Ilya Ilin, PhD (1) · Jeffrey Zacher, MD (1) · Jo Collier, Dr,MB, ChB (1) · Job F.M. van Boven, PharmD, PhD (1)
PMID 17668184, PMID 21375098, PMID 29667449, PMID 29854448, PMID 30977980, PMID 34998508, PMID 36582243, PMID 38836697, PMID 40121179, PMID 8238213
1UG3DA048743-01 (1), 2014 (1), K23DK138320 (1), P01NS119159 (1), R42AG073059 (1)